Q177: Clinical Features Just Prior to the Preparative Regimen

Question 177: What was the recipient’s disease status immediately prior to the preparative regimen?

The pre-HCT disease status is determined by a disease assessment, such as hematologic testing, pathology study, and / or physician assessment. Indicate the recipient’s disease status immediately prior to the start of the preparative regimen / infusion, using the options as defined below:

• Stable cytopenia, no cytogenetic abnormalities (no MDS) should be selected if the recipient’s blood counts have remained stable and no cytogenetic abnormalities were noted on karyotyping.
• Stable cytopenia with cytogenetic abnormalities (no MDS) should be selected if the recipient’s blood counts have remained stable; however, cytogenetic abnormalities were noted on karyotyping.
• Progressive cytopenia should be indicated if the recipient’s platelet, red blood cell, or white blood cell count has decreased from the time of diagnosis to prior to the start of the preparative regimen.
• Myelodysplasia should be selected if the recipient’s Fanconi Anemia has progressed to MDS.
• Leukemia, untreated should be selected if the recipient’s Fanconi Anemia has progressed to Leukemia and no chemotherapy was given within six months of the start of the preparative regimen.
• Leukemia, treated should be selected if the recipient’s Fanconi Anemia has progressed to Leukemia and chemotherapy was started within 6 months of the preparative regimen.
  

*Disease Status Prior to Start of Preparative Regimen
If the disease status prior to the start of the preparative regimen is captured as acute leukemia then please ensure that the primary disease for HCT is reported as leukemia on the Pre-TED Disease Classification (2402) Form. The corresponding Acute Myelogenous Leukemia (AML) Pre-Infusion (2010) and Post-Infusion (2110) forms or the Acute Lymphocytic Leukemia (ALL) Pre-Infusion (2011) and Post-Infusion (2111) forms must also be completed.
If the presenting hematologic disorder is myelodysplasia then please ensure that the primary disease for HCT is reported as MDS on the Pre-TED Disease Classification (2402) Form. The corresponding Myelodysplastic Syndrome Pre-Infusion (2014) and Post-Infusion (2114) forms must also be completed.

Section Updates

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (if applicable)
.	.	.	.	.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.